drugset / Trial / NCT00301093
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Phase 1
Completed
3 enrolled
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy when given together with imatinib mesylate in treating patients with chronic phase chronic myelogenous leukemia.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-05
- Completion
- 2020-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GM-K562 cell vaccine | Vaccine | — | Subcutaneous |
| Background | Imatinib | Small molecule | — | Oral |